372 related articles for article (PubMed ID: 15769273)
21. Aldara activates TLR7-independent immune defence.
Walter A; Schäfer M; Cecconi V; Matter C; Urosevic-Maiwald M; Belloni B; Schönewolf N; Dummer R; Bloch W; Werner S; Beer HD; Knuth A; van den Broek M
Nat Commun; 2013; 4():1560. PubMed ID: 23463003
[TBL] [Abstract][Full Text] [Related]
22. Toll-like receptor 7 agonists and skin.
Novak N; Yu CF; Bieber T; Allam JP
Drug News Perspect; 2008 Apr; 21(3):158-65. PubMed ID: 18560614
[TBL] [Abstract][Full Text] [Related]
23. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
[TBL] [Abstract][Full Text] [Related]
24. Imiquimod in basal cell carcinoma: how does it work?
Dummer R; Urosevic M; Kempf W; Hoek K; Hafner J; Burg G
Br J Dermatol; 2003 Nov; 149 Suppl 66():57-8. PubMed ID: 14616353
[TBL] [Abstract][Full Text] [Related]
25. Gene expression in actinic keratoses: pharmacological modulation by imiquimod.
Lysa B; Tartler U; Wolf R; Arenberger P; Benninghoff B; Ruzicka T; Hengge UR; Walz M
Br J Dermatol; 2004 Dec; 151(6):1150-9. PubMed ID: 15606509
[TBL] [Abstract][Full Text] [Related]
26. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
[TBL] [Abstract][Full Text] [Related]
27. New insights into imiquimod's mechanisms of action.
Martín-García RF
J Drugs Dermatol; 2004; 3(3):247-9. PubMed ID: 15176157
[TBL] [Abstract][Full Text] [Related]
28. CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease.
Wenzel J; Lucas S; Zahn S; Mikus S; Metze D; Ständer S; von Stebut E; Hillen U; Bieber T; Tüting T
J Am Acad Dermatol; 2008 Mar; 58(3):437-42. PubMed ID: 18280341
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.
Urosevic M; Maier T; Benninghoff B; Slade H; Burg G; Dummer R
Arch Dermatol; 2003 Oct; 139(10):1325-32. PubMed ID: 14568837
[TBL] [Abstract][Full Text] [Related]
30. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
31. Imiquimod-induced hypertrophic lupus erythematosus-like reaction.
Safadi MG; Hassan S; Patel V; Viglione M; Zahner SL
Dermatol Online J; 2022 Aug; 28(4):. PubMed ID: 36259863
[TBL] [Abstract][Full Text] [Related]
32. Topical immunomodulation in dermatology: potential of toll-like receptor agonists.
Hengge UR; Ruzicka T
Dermatol Surg; 2004 Aug; 30(8):1101-12. PubMed ID: 15274700
[TBL] [Abstract][Full Text] [Related]
33. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle.
Berman B; Sullivan T; De Araujo T; Nadji M
Br J Dermatol; 2003 Nov; 149 Suppl 66():59-61. PubMed ID: 14616354
[TBL] [Abstract][Full Text] [Related]
34. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
[TBL] [Abstract][Full Text] [Related]
35. Imiquimod in dermatology: an overview.
Hanna E; Abadi R; Abbas O
Int J Dermatol; 2016 Aug; 55(8):831-44. PubMed ID: 27387373
[TBL] [Abstract][Full Text] [Related]
36. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.
Adams S; Kozhaya L; Martiniuk F; Meng TC; Chiriboga L; Liebes L; Hochman T; Shuman N; Axelrod D; Speyer J; Novik Y; Tiersten A; Goldberg JD; Formenti SC; Bhardwaj N; Unutmaz D; Demaria S
Clin Cancer Res; 2012 Dec; 18(24):6748-57. PubMed ID: 22767669
[TBL] [Abstract][Full Text] [Related]
37. Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children.
Badavanis G; Pasmatzi E; Monastirli A; Georgiou S; Tsambaos D
Acta Dermatovenerol Croat; 2017 Jul; 25(2):164-166. PubMed ID: 28871935
[TBL] [Abstract][Full Text] [Related]
38. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions.
Wenzel J; Bekisch B; Uerlich M; Haller O; Bieber T; Tüting T
Am J Clin Pathol; 2005 Jul; 124(1):37-48. PubMed ID: 15923172
[TBL] [Abstract][Full Text] [Related]
39. Beyond a decade of 5% imiquimod topical therapy.
A Gaspari A; Tyring SK; Rosen T
J Drugs Dermatol; 2009 May; 8(5):467-74. PubMed ID: 19537370
[TBL] [Abstract][Full Text] [Related]
40. CD4
Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
